Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Oppenheimer initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report released on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Quince Therapeutics has an average rating of “Buy” and a consensus price target of $8.00.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX opened at $1.37 on Monday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $60.28 million, a P/E ratio of -1.10 and a beta of 0.71. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The stock has a 50 day moving average of $1.49 and a 200-day moving average of $1.44.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. As a group, equities research analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Anfield Capital Management LLC acquired a new stake in Quince Therapeutics during the fourth quarter worth approximately $50,000. Virtu Financial LLC bought a new stake in shares of Quince Therapeutics during the 4th quarter valued at $55,000. Two Sigma Investments LP acquired a new stake in shares of Quince Therapeutics during the 4th quarter worth $57,000. Northern Trust Corp increased its position in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after purchasing an additional 16,501 shares during the period. Finally, Scharf Investments LLC bought a new position in shares of Quince Therapeutics in the fourth quarter worth $170,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.